Updated Jul 16, 2026
Dentzer James E has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
James E. Dentzer is the President and CEO of Imunon, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for various diseases. He has also held director roles at CURIS, Inc.
| Role | President & CEO, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | IMNN | Imunon, Inc. | A — Grant or award | 11.1K | $2.20 | $25K |
| 2026-03-23 | CRIS | CURIS INC | J — Other acquisition / disposition | 133.3K | — | |
| 2025-08-04 | IMNN | Imunon, Inc. | A — Grant or award | 3.3K | $9.20 | $31K |
James E. Dentzer is the President and CEO of Imunon, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for various diseases. He has also held director roles at CURIS, Inc.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Dentzer James E profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.